Direct anti-thrombin inhibitors such as hirudin have theoretical advantages over heparin. Two large studies in acute coronary syndromes were designed to test the thrombin hypothesis by demonstrating improved outcomes in hirudin treated patients. TIMI 9 assessed the effect of hirudin in patients with ST elevation receiving thrombolytic therapy. GUSTO 2 assessed the full spectrum of acute coronary syndromes of ST elevation and non-ST elevation. Over 15,000 patients were entered into the studies and no major benefit was demonstrated for hirudin. This may, however, relate to endpoints measured and the timing of the anti-thrombin.
|Number of pages||3|
|Journal||Australian and New Zealand Journal of Medicine|
|Publication status||Published - 1 Aug 1998|
- Anti-thrombin inhibitors
- GUSTO 2b study
- TIMI 9a